Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNASDAQ:DRUGNASDAQ:MNPRNASDAQ:SGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.68+7.0%$1.76$1.05▼$4.13$364.98M1.96618,762 shs706,988 shsDRUGBright Minds Biosciences$27.61-0.7%$30.73$0.93▼$79.02$194.49M-5.75828,436 shs19,978 shsMNPRMonopar Therapeutics$37.11-2.4%$36.97$1.72▼$54.30$226.93M1.11359,982 shs19,857 shsSGTXSigilon Therapeutics$22.47$22.02$3.77▼$28.00$56.40M4.1262,902 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+18.71%+186.38%+100.65%+3.81%DRUGBright Minds Biosciences0.00%+6.19%-13.88%-19.97%+2,365.18%MNPRMonopar Therapeutics0.00%+15.72%-12.41%+30.49%+821.99%SGTXSigilon Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics2.5128 of 5 stars3.52.00.00.03.90.80.6DRUGBright Minds Biosciences3.3957 of 5 stars3.65.00.00.03.42.50.0MNPRMonopar Therapeutics2.9756 of 5 stars3.45.00.00.02.62.50.0SGTXSigilon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75110.60% UpsideDRUGBright Minds Biosciences 3.25Buy$83.25201.52% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3349.11% UpsideSGTXSigilon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SGTX, MNPR, DRUG, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/15/2025ADCTADC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/31/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.003/31/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$75.82M4.81N/AN/A($1.93) per share-1.91DRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ASGTXSigilon Therapeutics$12.94M4.36N/AN/A$15.68 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$240.05M-$1.45N/AN/AN/A-300.00%N/A-61.33%8/5/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-5.85%-5.68%8/13/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)SGTXSigilon Therapeutics-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/ALatest SGTX, MNPR, DRUG, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/27/2025Q4 2024ADCTADC Therapeutics-$0.35-$0.29+$0.06-$0.29$19.01 million$19.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASGTXSigilon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.924.68DRUGBright Minds BiosciencesN/A126.0111.31MNPRMonopar TherapeuticsN/A5.415.41SGTXSigilon TherapeuticsN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%DRUGBright Minds Biosciences40.52%MNPRMonopar Therapeutics1.83%SGTXSigilon TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics4.10%DRUGBright Minds Biosciences42.66%MNPRMonopar Therapeutics20.50%SGTXSigilon Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million92.73 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableSGTXSigilon Therapeutics622.51 million2.35 millionNot OptionableSGTX, MNPR, DRUG, and ADCT HeadlinesRecent News About These CompaniesRegenxbio expands MPS I gene therapy trial after first look at dataAugust 29, 2024 | pharmaphorum.comLilly & Co Eli's Net WorthMay 1, 2024 | benzinga.comMCRB Seres Therapeutics, Inc.April 14, 2024 | seekingalpha.comBeam Therapeutics Inc.October 22, 2023 | wsj.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | markets.businessinsider.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.August 1, 2023 | finance.yahoo.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 31, 2023 | msn.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...July 21, 2023 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 18, 2023 | markets.businessinsider.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 6, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJuly 3, 2023 | msn.comShares of Cambridge biotech Sigilon soar after company OKs Eli Lilly buyoutJune 30, 2023 | wickedlocal.comLilly of the valley provides big bounce-back for Sigilon via T1D takeoverJune 30, 2023 | bioworld.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | benzinga.comEli Lilly to buy Sigilon Therapeutics on a massive premiumJune 29, 2023 | invezz.comModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finance.yahoo.comEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | finanznachrichten.deHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsJune 29, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunWith Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderSGTX, MNPR, DRUG, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$3.68 +0.24 (+6.98%) Closing price 06/6/2025 03:59 PM EasternExtended Trading$3.73 +0.05 (+1.47%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Bright Minds Biosciences NASDAQ:DRUG$27.61 -0.20 (-0.72%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$28.31 +0.70 (+2.55%) As of 06/6/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Monopar Therapeutics NASDAQ:MNPR$37.11 -0.90 (-2.37%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$37.08 -0.02 (-0.07%) As of 06/6/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Sigilon Therapeutics NASDAQ:SGTXSigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
